Slide 1
Research Group Normal and Malignant Stem Cells

Andreas Trumpp
Group Leader

Lab News HSC Group

May 03, 2022

CRISPR-Cas9 mediated generation of a conditional poly(A) binding protein nuclear 1 (Pabpn1) mouse model reveals an essential role for hematopoietic stem cells

Apr 28, 2022

Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs.

Apr 28, 2022

Tumors on withdrawal: Amino acid deficiency shrinks childhood tumors

Apr 28, 2022

ERC Advanced Grant for Andreas Trumpp

Dec 14, 2021

High recognition for Andreas Trumpp

Sep 01, 2021

Ferroptosis: Mechanism and Diseases

Jun 10, 2021

Mouse multipotent progenitor 5 cells are located at the interphase between hematopoietic stem and progenitor cells

Mar 22, 2021

MutaSeq: Single-cell analysis of leukemic stem cells - Cooperation with Velten and Steinmetz Lab published in Nature Communications

Jan 27, 2021

How blood stem cells maintain their lifelong potential for self-renewal - New publication in Nature Communications

Making cancer stem cells visible to the immune system - New results may enable innovative treatment concept against leukemia (New publication in Nature)

NK cells (red) attack normal leukemia cells (green). Leukemia stem cells (blue), on the other hand, suppress NKG2DL expression at their surface and thus escape destruction by the immune system. © Schürch/Lengerke, University and University Hospital of Basel
NK cells (red) attack normal leukemia cells (green). Leukemia stem cells (blue), on the other hand, suppress NKG2DL expression at their surface and thus escape destruction by the immune system. © Schürch/Lengerke, University and University Hospital of Basel

Leukemia stem cells protect themselves against the immune defense by suppressing a target molecule for natural killer (NK) cells. This protective mechanism can be tricked with drugs. The exciting finding has been made by colleagues of the Trumpp team from HI-STEM and DKFZ together with the laboratories of Claudia Lengerke (Basel) and Helmut Salih (Tübingen) and was now published in Nature. Together with our collaborators, we now want to develop new therapeutic approaches based on these results.

Update: July 26,2019: The article has been featured in Research Watch at Cancer Discovery: PARP1 Inhibition Overcomes Immune Escape of Leukemic Stem Cells from NK cells

Read more:

  • DKFZ Press Release
  • Read the Paper at Nature:
    Anna M. Paczulla, Kathrin Rothfelder, Simon Raffel, Martina Konantz, Julia Steinbacher, Hui Wang, Claudia Tandler, Marcelle Mbarga, Thorsten Schaefer, Mattia Falcone, Eva Nievergall, Daniela Dörfel, Pauline Hanns, Jakob R. Passweg, Christoph Lutz, Juerg Schwaller, Robert Zeiser, Bruce R. Blazar, Michael A. Caligiuri, Stephan Dirnhofer, Pontus Lundberg, Lothar Kanz, Leticia Quintanilla-Martinez, Alexander Steinle, Andreas Trumpp, Helmut R. Salih, Claudia Lengerke: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.
    Nature 2019, DOI: 10.1038/s41586-019-1410-1
  • Research Watch at Cancer Discovery: PARP1 Inhibition Overcomes Immune Escape of Leukemic Stem Cells from NK cells